Parker Bioscience’s UK site to see multi-million dollar investment through 2018

By Melissa Fassbender

- Last updated on GMT

Getty/Norasit Kaewsai
Getty/Norasit Kaewsai
Parker Bioscience’s UK-based site will be expanded as part of a multi-million dollar phased investment program to be completed throughout 2018.

Parker Hannifin has announced a major investment in its Parker Bioscience division, which supplies and delivers systems for upstream and downstream pharmaceutical and biopharmaceutical manufacturing. The division has sites in Birtley, UK and Oxnard, CA in the US.

The investment will expand Parker Bioscience’s laboratory, clean room, office and warehouse facilities. According to the company, it also will make the division’s Birtley premises “one of the most modern manufacturing sites for integrated bioprocessing solutions in EMEA.”

Mike Brailsford, General Manager at Parker Bioscience, said: “The increased capacity will help us to offer larger scale services to biopharmaceutical manufacturers in Europe and across the globe, and is a major milestone in the division’s growth.”

Parker Bioscience has not responded to a request for comment.

Related news

Related products

show more

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Thermo Fisher Scientific - Biosciences | 01-Jan-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Create Better Biologic Treatments with Catalent

Create Better Biologic Treatments with Catalent

Catalent | 06-Dec-2022 | Product Brochure

Your biologics possess a high level of complexities and technical challenges. That’s why development is key to ensuring the successful delivery of your...

Related suppliers

Follow us


View more